The Clock

The Scenario Is Just the Vehicle

A suspicious consulting fee, a frozen overseas contract, and a room deciding how to handle it quietly.

What This Lab Is Really About

That time itself is an enterprise risk. After someone speaks up, a narrow window opens that a company can only use if its own escalation, judgment, and decision-making move fast enough — and most organizations run it out without anyone ever deciding to.

The real discussion is not about a single consulting fee, nor is it really about the FCPA. It is about a narrow window to preserve a declination, a “prudent” quarter-long plan that quietly runs it out, and a governance gap where a report sat for months — passed reasonably from hand to hand — before it reached the people who could act on it.

You don’t lose this one because someone made a bad decision. You lose because everyone made reasonable decisions — too slowly.

This Is Not a Trial of the Vice President

Leadership receives credible evidence — emails, invoices, a hotline report, a suspicious payment — and must make decisions before every investigative question is answered.

The exercise is not about whether the VP is guilty; that is for the investigation. It is about the real executive question: when do we have enough information to act? The evidence is credible enough that waiting for certainty is itself a costly decision — and the harder truth is that this matter sat inside the organization for months before it reached this room.

Inject 1 · The Discovery

Leadership learns of the “localized consulting and research fee” paid through Castamar to the hospital physician, which freed the frozen contract. It is presented as a local European subsidiary matter. The room’s first instinct is to manage it discreetly — hand it to overseas counsel, keep it away from US investors before the round.

Inject 2 · The Careful Plan

The room designs a genuinely good plan: retain outside counsel, preserve privilege, suspend the VP, run forensic accounting, interview witnesses, preserve documents — all over the next quarter, quietly, before the round. It feels responsible and sophisticated. This is the trap closing. The room is meant to feel good about a measured, defensible approach.

Inject 3 · The Clock (the detonator)

A timeline appears — and so does the report’s destination. The same conduct was raised on an anonymous hotline roughly four months ago: assigned to Regional HR, referred to Regional Legal, raised with the Business Unit President, folded into the funding-round discussion — and never sent to Corporate Compliance. Every handoff was individually reasonable. None reached this room. Four months of silence have already weakened any claim that the company is acting promptly — and the employee, hearing nothing, has signaled they won’t stay quiet much longer.

Everything inverts. A voluntary self-disclosure generally has to come before the government learns of the conduct — so the moment that employee goes outside, the option is effectively gone, and the company’s own delay is what brought it to the edge. Self-report now, ahead of that, and a declination may still be on the table; let the careful quarter-long plan run, and the window closes. The question is no longer “should we disclose?” It is “we’ve had this for four months?”

“We’d never sit on something like this.”

No one in the room decided to. The report came in, and it quietly never reached the people who could act on it — and the calendar did the rest. By the time leadership is in the room, four months have already passed, spent by an organization that didn’t know its position was eroding. The exposure is the silence in the escalation chain, not anyone’s intent to bury it.

CEO — owns the company’s survival, the valuation, and the funding round; makes the final call and signals whether the company races to disclose or protect the deal.

General Counsel — owns the disclosure decision, the timeliness judgment, the “appropriate DOJ component” question, and what self-reporting before an internal investigation is even finished looks like.

Chief Compliance Officer — owns the reporting system that received the report months ago and didn’t escalate it. Not the villain — but the seat that has to explain where the report stopped.

CFO — weighs the valuation and the funding round against the cost of disclosing now: the deal impact, the penalty exposure if the window is missed, and what diligence will surface either way.

Board Member / Audit Committee Chair — owns the governance question the whole room is about to ask: how did nobody tell us the clock was running?

Does a Report Reach Leadership in Time

When an internal report comes in, does it escalate to leadership fast enough to act on — or can it sit for months in the chain, as this one did?

Who Is Watching the Clock

Does anyone treat the moment a report is received as the start of a window — or does the company only discover the clock once it’s nearly run out?

Do We Have a Self-Disclosure Playbook

Is there a pre-built framework for whether and when to self-report — or is the decision improvised under a deadline with a funding round on the line?

When Does Our Clock Start

If a report came in today, who in the organization would recognize the moment the window opened — and is “Day Zero” defined anywhere in writing?

0–10 min — Frame. A credible problem has surfaced; the room decides how to handle it, with the funding round in view.

10–30 min — Inject 1. The discovery, framed as a local matter. The “manage it discreetly” instinct surfaces.

30–50 min — Inject 2. The room builds a careful, quarter-long plan and feels good about it.

50–70 min — Inject 3. The reveal, the dead escalation chain, the window closing as the report’s frustration reaches the edge. The reckoning.

70–90 min — Reframe & commit. The surfacing questions, the “when did the clock start?” exercise, and the decisions the room carries out — escalation, a self-disclosure playbook, and a written definition of Day Zero.

Facilitator’s guide — run-of-show, timing, the rule of the room, the countdown reveal, and how to hold the line against a guilt-trial drift.

The three inject cards — sequenced for timed reveal, with Inject 3 (the countdown) held as the detonator.

Role briefs — one per seat (CEO, General Counsel, Chief Compliance Officer, CFO, Board/Audit Committee Chair), each with the pressure that seat carries.

Reframe & surfacing-question set — the “we’d never sit on this” turn, the four questions to leave open, and the “when did the clock start?” closing exercise.

Legal-context primer — plain-language, counsel-hedged: voluntary self-disclosure, the “as soon as reasonably practicable” timeliness standard, what preserves eligibility for a declination (and why the 120-day whistleblower exception is narrower than it sounds), and the real-world example of a company that earned one.

Commitments template — the escalation protocol that gets a report to leadership fast, a written “Day Zero” definition, a self-disclosure decision framework, and a clock owner.

Debrief one-pager — the takeaways and the homework, sized for a follow-up email to the room.

Part of the Executive Decision Lab™ line. Each Lab puts a leadership team inside a high-pressure decision where the right answer is obvious in principle and hard in practice. Explore the full line of Executive Decision Labs.